Delving into the Latest Updates on GM-109 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Target

GPR38

Mechanism

GPR38 antagonists(Motilin receptor antagonists)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Chugai Pharmaceutical Co., Ltd.

Active Organization

Chugai Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

There have been few reports on the effects of the brain-gut peptide motilin on the central nervous system (CNS). We administered motilin intracerebroventricularly to mice and investigated the effect of motilin on anxiety using an elevated plus-maze. Motilin produced a significant decrease in anxiety with an inverted U-shaped dose response. To determine whether the anxiolytic effect of motilin was mediated via motilin receptors in the brain, the effect of GM-109, a novel motilin receptor antagonist, was investigated. GM-109 showed a significant and dose-dependent antagonism on the motilin-induced anxiolytic effect. GM-109 administered alone had no effect on anxiety. These results suggest that motilin receptors are present in the brain and may have a role in anxiety and emotion.

100 Deals associated with GM-109

Login to view more data